plavix
sanofi winthrop industrie - klopidogrelhydrogensulfat - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - antithrombotic agents - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. forebygging av atherothrombotic og tromboemboliske hendelser i atrial fibrillationin voksne pasienter med atrieflimmer som har minst en risikofaktor for vaskulære hendelser, er ikke egnet for behandling med vitamin-k-antagonister og som har en lav risiko for blødning, clopidogrel er indisert i kombinasjon med asa for forebygging av atherothrombotic og tromboemboliske hendelser, inkludert hjerneslag.
dasatinib teva 70 mg
teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 70 mg
dasatinib teva 20 mg
teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 20 mg
dasatinib teva 50 mg
teva b.v. - dasatinibmonohydrat - tablett, filmdrasjert - 50 mg
budesonid teva 0.25 mg/ ml
teva b.v. - budesonid - inhalasjonsvæske til nebulisator, suspensjon - 0.25 mg/ ml
budesonid teva 0.125 mg/ ml
teva b.v. - budesonid - inhalasjonsvæske til nebulisator, suspensjon - 0.125 mg/ ml
budesonid teva 0.5 mg/ ml
teva b.v. - budesonid - inhalasjonsvæske til nebulisator, suspensjon - 0.5 mg/ ml
montelukast teva 5 mg
teva sweden ab - montelukastnatrium - tyggetablett - 5 mg
montelukast teva 4 mg
teva pharma b.v. (4) - montelukastnatrium - granulat - 4 mg
montelukast teva 10 mg
teva sweden ab - montelukastnatrium - tablett, filmdrasjert - 10 mg